Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to a prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy by assessing clinical response compared with guselkumab monotherapy.


Clinical Trial Description

PsA is a chronic inflammatory multi-faceted disease that impacts the peripheral and axial joints, soft tissues, and skin. Guselkumab is a fully human monoclonal antibody (mAb) directed against the p19 subunit of interleukin (IL)-23, blocks the binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23 specific intracellular signaling, subsequent activation, and cytokine production. Golimumab is a fully human anti-TNF-alpha mAb that binds to TNF-alpha with high affinity, prevents binding to its receptors, thereby inhibiting the biological activity of TNF-alpha and resulting in limited production or activity of inflammatory cytokines, thereby providing therapeutic benefit in various chronic inflammatory disorders, including PsA. This study will consist of a Screening Phase (up to 6 weeks), Double-blind Phase from Weeks 0 to 24 which includes the active treatment phase and the primary efficacy visit (Week 24), and Safety Follow-up Phase from Week 24 to Week 36. Key safety assessments will include adverse events (AEs), clinical laboratory safety tests (hematology and chemistry), vital signs, monitoring for injection-site and hypersensitivity reactions, and early detection of active tuberculosis (TB). The total duration of the study is up to 42 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05071664
Study type Interventional
Source Janssen Research & Development, LLC
Contact Study Contact
Phone 844-434-4210
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date October 15, 2021
Completion date February 17, 2023

See also
  Status Clinical Trial Phase
Completed NCT02181673 - A Study of Golimumab in Participants With Active Psoriatic Arthritis Phase 3
Terminated NCT00090129 - Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis Phase 3
Not yet recruiting NCT04936308 - Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent Phase 3
Withdrawn NCT03625089 - Impact of Nurse-led Programme With Carotid Ultrasound on Addressing Cardiovascular Risk in Patients With Arthritis N/A
Completed NCT00938015 - Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis N/A
Suspended NCT03703934 - Central Pain Mechanisms in Patients With Hand-Osteoarthritis, Psoriatic Arthritis and Healthy Controls
Completed NCT02436785 - Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening? N/A
Recruiting NCT03853395 - BIOTIPRA: BIOmarker-guided Treatment Decisions In Psoriatic and Rheumatoid Arthritis N/A
Completed NCT02294227 - 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis Phase 3
Completed NCT00998829 - Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis N/A
Completed NCT00760669 - An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants Phase 4
Completed NCT00367237 - Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422) Phase 3
Completed NCT00051623 - A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis Phase 3
Withdrawn NCT04680676 - A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis Phase 2
Completed NCT03008590 - Low Dose Naltrexone for Chronic Pain From Arthritis Phase 2
Completed NCT03796858 - A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy Phase 3
Completed NCT01087788 - Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis Phase 3
Completed NCT01077362 - A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents Phase 3
Terminated NCT00273858 - Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis N/A
Terminated NCT00239720 - hOKT3gamma1 (Ala-Ala) for the Treatment of Psoriatic Arthritis Phase 2